GI Innovation and MSD partner for trial of GI-102 and Keytruda regimen for cancer
In preclinical studies, GI-102 monotherapy led to complete tumour regression in 60% of mice with liver cancer.
27 August 2024
27 August 2024
In preclinical studies, GI-102 monotherapy led to complete tumour regression in 60% of mice with liver cancer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.